-
公开(公告)号：US20250152565A1
公开(公告)日：2025-05-15
申请号：US19020135
申请日：2025-01-14
Applicant: UNIVERSITÄTSSPITAL BASEL
Inventor： Matthias Emanuel LIECHTI , Friederike Sophie HOLZE
IPC: A61K31/437 , A61K45/06 , A61P25/22
Abstract: A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.
-
公开(公告)号：US20240138889A1
公开(公告)日：2024-05-02
申请号：US18280020
申请日：2022-03-03
Applicant: UNIVERSITÄTSSPITAL BASEL
Inventor： Henrik ECKARDT
CPC classification number: A61B17/8066 , A61B17/8052 , A61F2/30771 , A61F2002/30784
Abstract: An osteosynthesis plate as replacement of a synarthrosis includes two fixation plate segments for securing the osteosynthesis plate to two bones. The osteosynthesis plate has a connecting segment interconnecting the two fixation plate segments, the connecting segments protruding from the fixation plate segments.
-
公开(公告)号：US20240057936A1
公开(公告)日：2024-02-22
申请号：US18271416
申请日：2022-01-12
Applicant: Hoffmann-La Roche Inc. , Universitätsspital Basel
Inventor： Martin Christian STRAHM , Yan-Ping ZHANG , Qian ZHOU
CPC classification number: A61B5/4803 , G10L25/18 , G10L25/21 , G10L25/66 , G10L25/93 , G10L25/90 , G10L15/05 , G10L2025/937
Abstract: Methods of assessing the pathological and/or physiological state of a subject, methods of monitoring a subject with heart failure or a subject that has been diagnosed as having or being at risk of having a condition associated with dyspnea and/or fatigue, and methods of diagnosing a subject as having decompensated heart failure are provided. The methods comprise obtaining a voice recording from a word-reading test from the subject, wherein the voice recording is from a word-reading test comprising reading a sequence of words drawn from a set of n words and analysing the voice recording, or a portion thereof. The analysing can comprise identifying a plurality of segments of the voice recording that correspond to single words or syllables; determining the value of one or more metrics selected from the breathing %, unvoicing/voicing ratio, voice pitch and correct word rate at least in part based on the identified segments; and comparing the value of the one or more metrics with one or more respective reference values. Related systems and products are also described.
-
公开(公告)号：US11801256B2
公开(公告)日：2023-10-31
申请号：US17692105
申请日：2022-03-10
Applicant: Universitätsspital Basel
Inventor： Matthias Emanuel Liechti , Anna Margarete Becker
IPC: A61K31/675 , A61P25/22 , A61P25/24 , A61K31/343
CPC classification number: A61K31/675 , A61K31/343 , A61P25/22 , A61P25/24
Abstract: A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.
-
公开(公告)号：US20230000799A1
公开(公告)日：2023-01-05
申请号：US17883502
申请日：2022-08-08
Applicant: Universitätsspital Basel
Inventor： Matthias Emanuel LIECHTI
IPC: A61K31/137 , A61P25/00
Abstract: A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20220088144A1
公开(公告)日：2022-03-24
申请号：US17422193
申请日：2020-01-13
Applicant: UNIVERSITÄTSSPITAL BASEL
Inventor： Marc DONATH
IPC: A61K38/20 , A61K31/7048 , A61K31/7042 , A61K31/351 , A61K31/382 , C07K16/24 , C07K16/28 , A61P3/08
Abstract: The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin-1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric surgery.
-
公开(公告)号：US20160158410A1
公开(公告)日：2016-06-09
申请号：US14906806
申请日：2014-07-21
Inventor： Prasad V. SHASTRI , Andrea BANFI , Aurelien FORGET , Roberto GIANNI-BARRERA
CPC classification number: A61L27/20 , A61K9/0019 , A61K9/06 , A61K38/18 , A61K47/36 , A61L27/22 , A61L27/3633 , A61L27/52 , A61L27/54 , A61L2300/414 , A61L2400/06
Abstract: Injectable hydrogels comprising polysaccharides based on disaccharides the backbones of which form an α-helix structure and in which in at least 10% of the disaccharide units the primary hydroxyl groups are oxidized.
Abstract translation: 可注射水凝胶，其包含基于二糖的多糖，其主链形成α-螺旋结构，并且其中在至少10％的二糖单元中伯羟基被氧化。
-
公开(公告)号：US11648103B2
公开(公告)日：2023-05-16
申请号：US16215690
申请日：2018-12-11
Applicant: UNIVERSITÄTSSPITAL BASEL
Inventor： Bernhard Winkler , Martin Grapow , Friedrich Eckstein , Aldo Ferrari , Dimos Poulikakos , Simone Bottan , Maximilian Fischer , Tobias Lendenmann
CPC classification number: A61F2/07 , A61F2/06 , A61F2/062 , A61F2/90 , A61F2002/0086 , A61F2002/068 , A61F2002/072 , A61F2210/0014 , A61F2210/0076 , A61F2250/003 , A61F2250/0026 , A61F2250/0051 , A61F2310/00011 , A61F2310/00982 , C12N1/20
Abstract: The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
-
公开(公告)号：US20220347169A1
公开(公告)日：2022-11-03
申请号：US17869896
申请日：2022-07-21
Applicant: Universitätsspital Basel
Inventor： Matthias Emanuel LIECHTI , Patrick Raphael VIZELI
IPC: A61K31/4745 , C12Q1/6876
Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.
-
20.发明授权公开(公告)号：US11364221B2
公开(公告)日：2022-06-21
申请号：US17549807
申请日：2021-12-13
Applicant: Universitätsspital Basel
Inventor： Matthias Emanuel Liechti
Abstract: A method of enhancing positive therapeutic effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen of MDMA administered in a dose of 20-200 mg, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a psychedelic in the same dosage form.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.022 seconds)
